Comprehensive Comparison of Liposomal Bupivacaine with Femoral Nerve Block for Pain Control Following Total Knee Arthroplasty: An Updated Systematic Review and Meta-Analysis

Yuan Liu, MD, Jun-feng Zeng, MD, Yi Zeng, MD, Yuan-gang Wu, MD, Xian-chao Bao, MD, Bin Shen, MD, PhD

Department of Orthopaedics, West China Hospital, Sichuan University, Chengdu, China

To compare the efficacy of liposomal bupivacaine (LB) and femoral nerve block following total knee arthroplasty, we conducted this systematic review and meta-analysis. 11 trials with 2,908 patients were included in this study. The pooled data demonstrated that total morphine consumption equivalents during the hospital stay was significantly increased in FNB group. In addition, LB has significantly better outcome in view of the postoperative functional recovery, such as the odds of fall, the incidences of straight leg rise (SLR), the number of patients who can walk independently in the day of surgery, the ambulation distance at POD1, the number of patients discharged at POD1. Consistent with the faster functional recovery, liposomal bupivacaine shortens the length of hospital stay. However, there was no significant difference between LB and FNB in terms of Visual Analogue Score (VAS) during the hospital stay. All in all, liposomal bupivacaine has significantly better outcome in view of the postoperative functional recovery and the length of hospital stay compared with femoral nerve block following the total knee arthroplasty.

Key words: Femoral nerve block; Functional recovery; Liposomal bupivacaine; Pain control; Total knee arthroplasty

Introduction

To total knee arthroplasty (TKA) is a surgical procedure used to treat patients experiencing end-stage knee osteoarthritis, and over 700,000 TKA are performed annually in the United States. However, most patients still suffer postoperative pain. Inadequate pain control is usually related to a series of negative effects, such as obstructed functional recovery, extended length of hospital stay, and increased economic load. Optimal postoperative pain management is not only beneficial for early movement and better functional recovery but is also helpful in minimizing the length of stay in hospital and the risk of negative effects. Therefore, there is a need to explore the optimal perioperative pain management for patients undergoing TKA.

So far, at least three types of perioperative pain management following TKA have been explored in the published literature. However, the optimal treatment remains controversial. The first type includes oral or vein opiates, epidural analgesia, and patient-controlled analgesia (PCA). Although they are effective for use as auxiliary analgesia and pain control, adverse events including nausea, vomiting, respiratory depression, postoperative ileus, urinary retention, and physical dependence have been reported. The second type is peripheral nerve blocks, especially femoral nerve blocks (FNB). FNB are widely used following TKA to manage perioperative pain and decrease morphine dosage. However, FNB are associated with quadriceps weakness, which increases the risk of falls. In addition, quadriceps disability may last beyond 2 days after the cessation of FNB because of femoral nerve paralysis, which influenced the ability to engage in physical exercise after TKA. Third, periarticular injection is considered an alternative technique for pain control following TKA. Although bupivacaine is a familiar and relatively long acting anesthetic agent for local anesthesia, it

Address for correspondence Bin Shen, MD, PhD, Department of Orthopaedics, West China Hospital, Sichuan University, 37# Guoxue Road, Chengdu, 610041, China Tel: +86-13881878767; Fax: +86-028-85423438; Email: shenbin_1971@163.com

Received 7 August 2019; accepted 1 September 2019
Two of them compare the efficacy of LB with FNB following TKA.14,17 However, the conclusions they attain are not completely coherent, and there are two recently published studies not included.19,20 Furthermore, outcomes relating to postoperative functional recovery, such as falls, range of motion (ROM), and ambulation distance were added to the new meta-analysis. As a result, we performed this updated review and meta-analysis to comprehensively compare the efficacy of LB with FNB following TKA. In addition, we discussed the cost of different methods because more and more published articles have referred to the cost comparison between LB and FNB. We hypothesized that the efficacy of LB was superior to FNB following TKA in terms of postoperative functional recovery.

Materials and Methods

Searching
Randomized controlled trials (RCT) and cohort studies from electronic databases, including PubMed (since 1966), EMBASE (since 1980), the Cochrane Central Register of Controlled Trials (CENTRAL, since 1980), the Web of Science (since 1966), were systematically searched by two reviewers. “Total knee arthroplasty OR replacement,” “liposomal bupivacaine OR Exparel” and “femoral nerve block” were used as search key words. There was no limitation on language and locality. No grey or unpublished articles were included. Two reviewers independently assessed the studies, and any discrepancies were resolved by consultation with the authors. Because this study was a meta-analysis analyzing existing articles, ethical approval not necessary.

Inclusion Criteria
Studies were selected if they matched the following criteria in PICOS order: (i) Population, patients experiencing TKA who were demographically alike; (ii) Intervention, percutaneous injection of LB; (iii) Control intervention, FNB; (iv) Outcomes, postoperative pain management and functional recovery; and (v) Study design, RCT or retrospective cohort study.

To decrease the influence of mixed pain management, we excluded studies that included other strategies such as adductor canal blockade.

Data Screening
Two reviewers independently screened the information listed on a standard form designed to screen the correlative data from included studies. The data extracted included authors, the year of publication, study type, sample capacity, basic patient information (age, gender, and body mass index), anesthetic methods, follow up, and outcomes. Any disagreements were unified through discussion with other authors.

The primary outcome reflected the pain control, including the visual analogue score (VAS) and morphine consumption. Secondary outcomes reflected the functional recovery, including incidences of fall and straight leg rise (SLR), ROM, ambulation time, ambulation distance discharged time, and length of hospital stay (LOS).

Validity Evaluation
Based on the Cochrane Handbook, two reviewers respectively evaluated the methodological quality of included studies. A modified seven-point Jadad scale was adopted to evaluate the methodological quality for RCT, which consisted of five items, including randomization, concealment of allocation, double blinding, withdrawn, and dropped out.21,22 The study was regarded as an RCT of high quality if the Jadad score was greater than four points. Two reviewers evaluated the quality of non-RCT by using the methodological index for non-randomized studies scale (MINORS), which has a range of scores from 0 to 24.23

Unified consensus was obtained if there were any different opinions.

Statistical Analysis
We make use of the Review Manager 5.3 software to analyze pooled data. We use the effect value of mean differences (MD) or standard mean differences (SMD) to weigh the effect size for continuous outcomes. We use the effect value of relative risks (RR) to measure the effect size for dichotomous outcomes. We considered the result significantly different when a two-sided P-value was <0.05.

Subgroup Analysis
We use the I² statistic to test heterogeneity across the studies.24 We regarded a P-value ≤0.1 or an I² >50% as proof of heterogeneity. A random-effects model could make the synthesis of results with high heterogeneity more conservative than a fixed-effects model. Therefore, a random-effects model was used to eliminate the effect caused by high heterogeneity; a fixed-effects model was adopted when the heterogeneity was low. We performed subgroup analysis to investigate the source of heterogeneity.

Results

Search Results and Study Characteristics
A total of 343 relevant articles from electronic databases were identified based on the search strategy. A total of 159 duplicates were removed and 165 studies were excluded after reading the title and abstract. Based on the inclusion and exclusion criteria, 8 studies were excluded by reading the full text. Among them, Phillips et al.24 added adductor canal block (ACB) to analgesia in the LB group, which could produce bias by lowering the score of the VAS, so we removed it from the meta-analysis. Kim et al.25 reported the related outcomes but were excluded because of the repetition of data with another article included in our meta-analysis.
Finally, three RCT involving 457 patients and eight non-RCT involving 2451 patients that compared LB with FNB were included (Fig. 1). The baseline characteristics of each study are presented in Table 1. Five in eleven studies performed power analyses to estimate the sample size to acquire the significant result. The length of follow up ranged from 3 days to 1 year.

Validity Assessment
The methodological quality of three RCT was evaluated using the modified JADAD scale. For randomization, two were randomized by using sealed envelopes containing the allocation of the group, while the other did not describe the method of randomization. Both refer to the allocation concealment. The patients and surgeons were double blind in two RCT, while not in the other RCT. All three reported on withdrawals and dropouts. The MINORS scale was used to assess the methodological quality for eight non-RCT with scores varying from 16 to 24. The specific total score of each non-RCT is recorded in Table 2.

Outcomes of Postoperative Pain Management

Visual Analogue Score at POD0
Six studies involving 2349 patients referred to the visual analogue score (VAS) on the day of surgery (POD0). The final synthesis revealed that the LB is not significantly different from FNB (MD = 0.15, 95% CI: [-0.45, 0.74], P = 0.63; Fig. 2A). Because of the high heterogeneity ($\chi^2 = 42.98, df = 5, P < 0.00001, I^2 = 88%)$, a random-effects model was adopted. The heterogeneity is rooted in the different kinds of FNB according to the results of subgroup analysis (Table 3).

Visual Analogue Score at POD1
Five studies involving 1286 patients recorded the VAS on the first day after surgery (POD1). The final synthesis revealed that LB is not significantly different from FNB (MD = -0.09, 95% CI: [-0.79, 0.6], P = 0.79; Fig. 2B). Because of the high heterogeneity ($\chi^2 = 25.9, df = 4, P < 0.0001, I^2 = 85%)$, a random-effects model was adopted. The heterogeneity is rooted in the different
kinds of FNB according to the results of subgroup analysis (Table 3).

Visual Analogue Score at POD2
Three studies involving 551 patients mentioned the VAS on the second day after surgery (POD2)\textsuperscript{19,27,32}. The final synthesis revealed that LB is not significantly different from FNB ($MD = 0.07, 95\% CI: \([-0.26, 0.41]\), $P = 0.67; \text{Fig. 2C}$). A fixed-effects model was used because there was no statistical heterogeneity ($\chi^2 = 3.16, df = 2, P = 0.21, I^2 = 37\%)$.

Total Morphine Consumption
Six studies with 2027 patients recorded the amount of morphine consumption during the whole hospital period\textsuperscript{10,20,26,29,30,33}. The final synthesis revealed that the FNB group consumed significantly more morphine equivalents ($MD = −46.58, 95\% CI: \([-85.23, −7.94]\), $P = 0.02; \text{Fig. 3}$). Because of the high heterogeneity ($\chi^2 = 540.67, df = 5, P < 0.00001, I^2 = 99\%)$, a random-effects model was applied. The heterogeneity is rooted in the different kinds of FNB according to the results of subgroup analysis (Table 3).

Morphine Consumption at POD0
Three studies involving 413 patients recorded the amount of morphine consumption on the day of surgery (POD0)\textsuperscript{26,27,32}. The final synthesis revealed that LB is not significantly different from FNB ($MD = 1.4, 95\% CI: \([-2.65, 5.45]\), $P = 0.50; \text{Fig. 3}$). A fixed-effects model was adopted because there was no statistical heterogeneity ($\chi^2 = 4, df = 2, P = 0.14, I^2 = 50\%)$.

Morphine Consumption at POD1
Three studies involving 413 patients mentioned the amount of morphine consumption on the first day after surgery (POD1)\textsuperscript{26,27,32}. The final synthesis revealed that LB is not significantly different from FNB ($MD = −3.65, 95\% CI: \([-7.84, 0.54]\), $P = 0.09; \text{Fig. 3}$). A fixed-effects model was used because there was no statistical heterogeneity ($\chi^2 = 1.11, df = 2, P = 0.57, I^2 = 0\%)$.

Outcomes of Postoperative Functional Recovery

Range of Motion
Two studies involving 314 patients recorded the ROM in two groups\textsuperscript{19,26}. The final synthesis revealed that the FNB

---

**TABLE 1** The baseline characteristics of the included studies

| Studies        | SD          | Cases     | Mean age | Female | BMI     | Anesthesia | FNB | Dose of LB | CPM | Follow-up |
|----------------|-------------|-----------|----------|--------|---------|------------|-----|------------|-----|-----------|
| Broome (2014)  | Non-RCT     | 100/100   | —        | —      | —       | SA CFNB    | —  | —          | Oral morphine hydrocodone equivalents | 3 days     |
| Cien (2015)    | Non-RCT     | 65/57     | 62.6/61.9| 41/36  | 34.5/34.6| GA SFNB    | 266 mg LB | —          | Spinal morphine, tramadol, tapentadol, morphine and oxycodone acetaminophen | 1 month    |
| Emerson JR (2016) | Non-RCT    | 36/36     | 64.2/66.9| 22/26  | 34.7/32.5| GA CFNB    | 266 mg LB | —          | Oral, intravenous, and PCA morphine equivalents | 5 days     |
| Horn (2015)    | Non-RCT     | 16/16     | 63.8/66.1| 14/14  | —       | SA SFNB    | 266 mg LB | —          | Oral, intravenous, and PCA morphine equivalents | 2 days     |
| Kirkness (2016) | Non-RCT     | 134/134   | 67.6/67.1| 77/74  | 32.2/32.7| SA/GA CFNB | 266 mg LB | —          | Oral, intravenous, and PCA morphine equivalents | 3 days     |
| Marino (2018)  | RCT         | 32/33     | 64.2/62.3| 17/15  | 33.1/32.6| SA CFNB    | 266 mg LB | —          | IV hydromorphone, tramadol, morphine and oxycodone acetaminophen | 3 days     |
| Sporer 2016    | Non-RCT     | 325/272   | 65/63.4  | 202/168| 33.0/33.2| SA SFNB    | 266 mg LB | —          | IV morphine, Dilaudid, fentanyl and oxycodone | 4 weeks    |
| Surdam (2015)  | RCT         | 40/40     | 68.4/64.9| 21/23  | —       | SA SFNB    | 266 mg LB | —          | Oral hydromorphone equivalents | 1 year     |
| Talmo (2018)   | RCT         | 161/151   | 62.32/62.01| 73/81  | 30.06/30.71| SFNB 266 mg LB | — | — | Morphine equivalents | 3 days     |
| Torres (2017)  | Non-RCT     | 23/23     | 66.0/64.4| 14/14  | —       | SA CFNB    | 20 cc of LB in 40 cc in 0.9% NS | — | — | Oral narcotics, intravenous morphine | 3 days     |
| Yu (2016)      | Non-RCT     | 583/531   | 66/65    | 385/356| 32/32   | SA/GA SFNB | 20 cc of LB in 40 cc in 0.9% NS | — | — | Oral narcotics, intravenous morphine | 3 days     |

BMI, body mass index; CFNB, continuous femoral nerve block; CPM, concomitant pain management; FNB, femoral nerve block; GA, general anesthesia; LB, liposomal bupivacaine; RCT, randomized controlled study; SA, spine anesthesia; SD, study design; SFNB, single femoral nerve block.
group may have significantly higher ROM than the LB group ($MD = -5.99$, $95\% CI [-8.48, -3.51]$, $P < 0.00001$, Fig. 4A). A fixed-effects model was selected because there was no statistical heterogeneity ($\chi^2 = 0.39$, $df = 1$, $P = 0.53$, $I^2 = 0\%$).

The Occurrence of Falls
Three studies involving 1424 patients described the occurrence of a fall$^{19,26,33}$. The pooled data revealed that there were significantly more incidences of falls in the FNB group compared with the LB group ($RR = 0.34$, $95\% CI [0.12, 0.97]$, $P = 0.04$, Fig. 4B). A fixed-effects model was selected because there was no statistical heterogeneity ($\chi^2 = 0.75$, $df = 2$, $P = 0.69$, $I^2 = 0\%$).

Number of Patients Discharged at POD1
Four studies involving 594 patients described the number of patients discharged on the first day after surgery$^{20,26,28,32}$. The final synthesis revealed that significantly more patients in the LB group were discharged on the first day after surgery compared with the FNB group ($MD = 14.60$, $95\% CI [4.10, 51.99]$, $P < 0.0001$, Fig. 4C). A fixed-effects model was selected because there was no statistical heterogeneity ($\chi^2 = 0.23$, $df = 3$, $P = 0.97$, $I^2 = 0\%$).

Occurrence of Straight Leg Rise at POD 0
Two studies with 298 patients mentioned the occurrence of SLR on the day of surgery$^{19,26}$. The pooled data revealed that the LB group was not significantly different from the FNB group ($RR = 2.68$, $95\% CI [0.65, 11.01]$, $P = 0.17$; see appendix). A random-effects model was adopted because of the high heterogeneity ($\chi^2 = 10.79$, $df = 1$, $P = 0.001$, $I^2 = 91\%$).

Number of Patients Walking Independently at POD0
Two studies involving 348 patients reported on the number of patients who walked independently on the day of surgery$^{26,32}$. The final synthesis revealed that significantly more patients in the LB group walked on the day of surgery compared with the FNB group ($MD = 6.75$, $95\% CI [3.35, 13.61]$, $P < 0.0001$; see appendix). A fixed-effects model was selected because there was no statistical heterogeneity ($\chi^2 = 0.04$, $df = 1$, $P = 0.83$, $I^2 = 0\%$).

Ambulation Distance at POD1
Two studies involving 347 patients recorded the distance patients walked on the first day after surgery$^{26,32}$. The pooled data revealed that patients in the LB group walked significantly farther compared with those in the FNB group ($SMD = 0.43$, $95\% CI [0.22, 0.65]$, $P < 0.0001$; see appendix). A fixed-effects model was selected because there was no statistical heterogeneity ($\chi^2 = 0.21$, $df = 1$, $P = 0.64$, $I^2 = 0\%$).

Outcome of the Length of the Hospital Stay
Nine studies with 1651 patients offer detailed data on the length of hospital stay$^{10,19,20,26,28–32}$. The final synthesis revealed that LB was associated with a significantly shorter
length of hospital stay compared with FNB ($MD = -0.27$, 95% CI $[-0.41, -0.13]$, $P = 0.0001$, Fig. 5). A random-effects model was adopted because of the high heterogeneity ($\chi^2 = 17.13$, $df = 8$, $P = 0.03$, $I^2 = 53\%$) The heterogeneity is rooted in the different kinds of FNB according to the results of subgroup analysis (Table 3).
TABLE 3 The results of subgroup analysis

| Outcomes       | Subgroups | Studies | $\chi^2$ | MD and 95% CI          | $I^2$ (%) | $P$  |
|----------------|-----------|---------|----------|-------------------------|-----------|------|
| VAS at POD0    | CFNB      | 2       | 0.07     | 0.42 (−0.02, 0.86)      | 0         | 0.8  |
|                | SFNB      | 4       | 35.91    | 0.03 (−0.73, 0.78)      | 92        | <0.0001 |
| VAS at POD1    | CFNB      | 2       | 0.17     | 0.49 (0.09, 0.9)        | 0         | 0.68 |
|                | SFNB      | 3       | 23.53    | −0.48 (−1.54, 0.59)     | 91        | <0.0001 |
| Total morphine | CFNB      | 2       | 0.01     | −70.97 (−104.11, −37.83)| 0         | 0.93 |
|                | SFNB      | 4       | 535.92   | −36.51 (−82.86, 9.83)   | 99        | <0.0001 |
| LOS            | CFNB      | 4       | 1.85     | −0.36 (−0.53, −0.19)    | 0         | 0.6  |
|                | SFNB      | 5       | 11.82    | −0.22 (−0.41, −0.03)    | 66        | 0.02 |

Fig. 3 The results of meta-analysis for outcomes relating to the morphine consumption equivalents: (A) total amount of morphine consumption, (B) morphine consumption at POD0 and (C) morphine consumption at POD1.
Optimal pain management following TKA enables faster functional recovery and reduces postoperative complications and hospital costs. Accompanied with a steadily rising demand for TKA as the population ages, the obesity rate increases, and surgical techniques advance, both surgeons and patients have an appetite for more satisfactory perioperative pain management, faster functional recovery, and reduced hospital costs. Among the current perioperative pain management options, LB has been approved for use by the US FDA, and a series of clinical trials have proven that LB is safe and helpful for pain relief. FNB was used as a general method for postoperative pain control. Two published meta-analyses compared LB with FNB following TKA, but the conclusions they reached were not totally consistent. Ma et al. investigated one RCT and five non-RCT and concluded that LB provides similar postoperative pain relief and significantly reduces the consumption of morphine equivalents compared with FNB. However, Liu et al. analyzed two RCT and six non-RCT and concluded that LB provides a significant beneficial effect over FNB in terms of pain reduction, and decreased the total morphine consumption. In addition, none of them compared the functional recovery in the experimental and control groups. Furthermore, a new RCT indicated that pain scores were slightly lower in the LB group in the first 24 hours after TKA compared with LB. It was not clear which method is better in relation to pain relief and functional recovery.

Therefore, we perform this meta-analysis to judge whether LB is superior to FNB in terms of perioperative pain management and postoperative functional recovery after TKA. To our knowledge, this is the first meta-analysis that compared the postoperative functional recovery between LB and FNB. The most significant finding of this study was that the LB speeds up the postoperative functional recovery and decreases the length of stay compared with FNB.

In our study, the primary outcomes include the VAS and morphine consumption equivalents, both of which reflect the efficacy of pain relief following the TKA. The pooled data showed that the effectiveness of LB was the same
as the FNB for VAS during the hospital stay. However, the total morphine consumption in the LB group was significantly less compared with the FNB group ($MD = -46.58$, $95\% CI: [-85.23, -12.05], P = 0.02$), while the morphine consumption at POD0 and POD1 were not significantly different in two groups. This might be explained with two possible reasons. First, the lower amount of morphine consumption, the shorter the length of hospital stay ($MD = -0.27$, $95\% CI [-0.41, -0.13], P = 0.0001$). In this case, we cannot judge which group is superior in terms of pain control. Second, the lower amount of morphine consumption is the result of better efficacy of pain control in the LB group. In this case, we can indirectly conclude that LB is superior in terms of pain control in regard to the efficacy of pain control following TKA.

We measured the postoperative functional recovery including five items as the second outcome in our study, which was not involved in the two published meta-analyses. First, we compared the incidence of falls in the two groups. Several studies have previously found that FNB may be associated with the increase of falls. Paauwe et al. conducted a pilot study and found that there was a quantitative quadriceps weakness in 33% of patients with FNB following TKA. Sharma et al. performed a retrospective review of TKA patients after FNB versus no block demonstrated an increased ratio of falls of 33% compared to the LB group ($RR = 0.34$, $95\% CI [0.12, 0.97], P = 0.04$).

Second, early and safe ambulation is crucial for physical exercise after TKA; thus, we compared the number of patients who walked independently on the day of surgery (POD0) and the ambulation distance at POD1 between LB and FNB groups. The data demonstrated that patients in the LB group walked earlier and ambulated further than those in the FNB group. This was consistent with the finding for falls. Third, to assess the functional recovery of knee joints, we compared the ROM and the number of patients who could perform straight leg rise (SLR) between LB and FNB. We found a trend that patients in the LB group could more easily perform SLR than those in the FNB group (Fig. 4). However, the results were significant for the fixed-effects model but not the random-effects model. We suspected that the significant outcome might result when a bigger sample size is used. Regarding ROM, two RCTs were included in the comparison of ROM. The pooled data showed that the ROM in the FNB group was higher than in the LB group, and this was associated with the time of ROM measurement, which is within 24 hours after surgery. The VAS within 24 hours in these two studies were both significantly higher in the LB group than in the FNB group. Fourth, in consideration of a trend that patients in the LB group can exercise earlier, we compared the number of patients discharged at POD1 and concluded that more patients in the LB group were discharged to home on POD1 ($MD = 14.60$, $95\% CI [4.10, 51.99], P < 0.0001$). Eventually, LB decreased the length of hospital stay ($MD = -0.22$, $95\% CI [-0.31, -0.13], P < 0.00001$).

To summarize these results, we explored the reasons for patients in the LB group having a faster functional recovery including five items as the second outcome in our study, which was not involved in the two published meta-analyses. First, we compared the incidence of falls in the two groups. Several studies have previously found that FNB may be associated with the increase of falls. Paauwe et al. conducted a pilot study and found that there was a quantitative quadriceps weakness in 33% of patients with FNB following TKA. Sharma et al. performed a retrospective review of TKA patients after FNB versus no block demonstrated an increased ratio of falls of 1.6 versus 0.4. This was consistent with our finding ($RR = 0.34$, $95\% CI [0.12, 0.97], P = 0.04$). Second, early and safe ambulation is crucial for physical exercise after TKA; thus, we compared the number of patients who walked independently on the day of surgery (POD0) and the ambulation distance at POD1 between LB and FNB groups. The data demonstrated that patients in the LB group walked earlier and ambulated further than those in the FNB group. This was consistent with the finding for falls. Third, to assess the functional recovery of knee joints, we compared the ROM and the number of patients who could perform straight leg rise (SLR) between LB and FNB. We found a trend that patients in the LB group could more easily perform SLR than those in the NB group (Fig. 4). However, the results were significant for the fixed-effects model but not the random-effects model. We suspected that the significant outcome might result when a bigger sample size is used. Regarding ROM, two RCTs were included in the comparison of ROM. The pooled data showed that the ROM in the FNB group was higher than in the LB group, and this was associated with the time of ROM measurement, which is within 24 hours after surgery. The VAS within 24 hours in these two studies were both significantly higher in the LB group than in the FNB group. Fourth, in consideration of a trend that patients in the LB group can exercise earlier, we compared the number of patients discharged at POD1 and concluded that more patients in the LB group were discharged to home on POD1 than in the FNB group ($MD = 14.60$, $95\% CI [4.10, 51.99], P < 0.0001$). Eventually, LB decreased the length of hospital stay ($MD = -0.22$, $95\% CI [-0.31, -0.13], P < 0.00001$).
recovery than those in the FNB. After comparing the detailed information regarding the two analgesia, it was evident that the effective mechanisms of the two methods are completely different. The LB was injected into the surrounding site of the surgery, but the analgesia drugs were injected into the femoral nerve in the FNB group. This produced the side effect of femoral nerve palsy, decreasing the strength of quadriceps, so that the patients in the FNB group had a longer period of functional recovery.

To obtain more convincing pooled data in the comparison of postoperative pain management, future studies should pay more attention to these points. First, it is best to measure the pain score at different time points and to calculate the mean every day to decrease the subjective discrepancies, and to use a unified pain scale such as the VAS to decrease objective discrepancies. Second, to reduce avoidable influences on VAS, it is best to make concomitant pain management consistent. Third, a better functional recovery is an important reflection on better postoperative pain management. Consequently, future studies could add the postoperative functional recovery into the comparison. Fourth, besides the comparison inside the hospital, it is important to evaluate the prospective outcome with a long follow up to explore whether the different analgesia influences the final outcome of TKA.

There are several limitations in our study. First, only two RCT were included; the statistical validity would increase if we included more RCT. Second, four trials had fewer than 50 patients in each group and follow up was not long enough. Third, the heterogeneity of several results is high, which might influence the reliability of our study. Fourth, because of incomplete data, we did not compare the incidence of adverse events such as nausea and vomiting, which is important to reflect the adverse impacts for the two groups.

**Conclusion**

Liposomal bupivacaine significantly reduced the amount of total morphine consumption and sped up the postoperative functional recovery, reducing the length of hospital stay compared with FNB following TKA.

**Acknowledgments**

All authors have no financial or personal relationships with other people or organizations that could inappropriately influence this work.

**References**

1. Kurtz SM, Ong KL, Lau E, et al. International survey of primary and revision total knee replacement. Int Orthop, 2011, 35: 1783–1789.
2. Wyld V, Rooker J, Halliday L, Blom A. Acute postoperative pain at rest after hip and knee arthroplasty: severity, sensory qualities and impact on sleep. Orthop Traumatol Surg Res, 2011, 97: 139–144.
3. Busch CA, Shore BJ, Bhandari R, et al. Efficacy of periarticular multimodal drug injection in total knee arthroplasty. A randomized trial. J Bone Joint Surg Am, 2006, 88: 959–963.
4. Ma J, Zhang W, Yao S. Liposomal bupivacaine infiltration versus femoral nerve block for pain control in total knee arthroplasty: a systematic review and meta-analysis. Int J Surg, 2016, 36: 44–55.
5. Lu J, Deng X, Jiang T. Combined femoral and sciatic nerve block versus femoral and local infiltration anesthesia for pain control after total knee arthroplasty: a meta-analysis of randomized controlled trials. J Orthop Surg Res, 2016, 11: 158.
6. Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. J Pain, 2002, 3: 159–180.
7. Choy WS, Lee SK, Kim KJ, Kam BS, Yang DS, Bae KW. Two continuous femoral nerve block strategies after TKA. Knee Surg Sports Traumatol Arthrosc, 2011, 19: 1901–1908.
8. Paul JE, Aya A, Hurbutl L, et al. Femoral nerve block improves analgesia outcomes after total knee arthroplasty: a meta-analysis of randomized controlled trials. Anesthesiology, 2010, 113: 1144–1162.
9. Brull R, McCartney CJ, Chan WW, El-Beheiry H. Neurological complications after regional anesthesia: contemporary estimates of risk. Anesth Analg, 2007, 104: 965–974.
10. Sporer SM, Rogers T. Postoperative pain management after primary total knee arthroplasty: the value of liposomal bupivacaine. J Arthroplasty, 2016, 31: 2603–2607.
11. Barrington JW, Daluy DF, Emerson RH Jr, Hawkins JU, Joshi GP, Stubenberg BN. Improving patient outcomes through advanced pain management techniques in total hip and knee arthroplasty. Am J Orthop (Belle Mead NJ), 2011, 42: 51–520.
12. Sun H, Huang Z, Zhang Z, Liao W. A meta-analysis comparing liposomal bupivacaine and traditional periarticular injection for pain control after total knee arthroplasty. J Knee Surg, 2019, 32: 251–258.
13. Wang X, Xiao L, Wang Z, Zhao G, Ma J. Comparison of peri-articular liposomal bupivacaine and standard bupivacaine for post-surgical analgesia in total knee arthroplasty: a systematic review and meta-analysis. Int J Surg, 2017, 39: 238–248.
14. Yu ZX, Yang ZZ, Yao LL. Effectiveness of liposome bupivacaine for postoperative pain control in total knee arthroplasty: a PRISMA-compliant meta-analysis of randomized controlled trials. Med (Baltimore), 2018, 97: e0171.
15. Fan L, Zhu C, Pan P, et al. The comparison of local infiltration analgesia with peripheral nerve block following Total knee Arthroplasty (TKA): a systematic review with meta-analysis. J Arthroplasty, 2015, 30: 1664–1671.
16. Singh PM, Borle A. Role of periarticular liposomal bupivacaine infiltration in patients undergoing total knee arthroplasty-a meta-analysis of comparative trials. J Arthroplasty, 2017, 32: 675–688.
17. Liu SQ, Chen X, Yu CC, et al. Comparison of periarticular anesthesia with liposomal bupivacaine with femoral nerve block for pain control after total knee arthroplasty: a PRISMA-compliant meta-analysis. Med (Baltimore), 2017, 96: e6462.
18. Huang MJ, Du Y, Ma JX, He W, Fu L, Ma XL. The efficacy of liposomal bupivacaine using periarticular injection in total knee arthroplasty: a systematic review and meta-analysis. J Arthroplasty, 2017, 32: 1395–1402.
19. Talmo CT, Kent SE, Fredette AN, Anderson MC, Hassan MK, Mattingly DA. Prospective randomized trial comparing femoral nerve block with intraoperative local anesthetic injection of liposomal bupivacaine in total knee arthroplasty. J Arthroplasty, 2018, 33: 3474–3478.
20. Torres EG, Anderson AB, Broome B, Geary SP, Burnikel B. Total knee arthroplasty performed with long-acting liposomal bupivacaine versus femoral nerve catheter. Am J Orthop (Belle Mead NJ), 2017, 46: E414–E418.
21. Hartling L, Ospina M, Liang Y, et al. Risk of bias versus quality assessment of randomised controlled trials: cross sectional study. BMJ, 2009, 339: b4012.
22. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996, 17: 1–12.
23. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chiappini P. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg, 2003, 73: 712–718.
24. Phillips J, Doshi A. Effects of liposomal bupivacaine with adductor canal block on pain and functional outcomes in patients undergoing total knee arthroplasty. Ann Pharmacother, 2016, 50: 706–711.
25. Kim K, Elbuluk A, Yu S, Iorio R. Cost-effective peri-operative pain management: assuring a happy patient after total knee arthroplasty. Bone Joint J, 2018, 100: 55–61.
26. Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplasty, 2015, 30: 325–329.
27. Marino J, Scuderi G, Dowling O, Farquhar R, Freycinet B, Overdyk F. Periarticular knee injection with liposomal bupivacaine and continuous femoral nerve block for postoperative pain management after total knee arthroplasty: a randomized controlled trial. J Arthroplasty, 2019, 34: 495–500.
28. Broome CB, Burnikel B. Novel strategies to improve early outcomes following total knee arthroplasty: a case control study of intra articular injection versus femoral nerve block. Int Orthop, 2014, 38: 2087–2089.
29. Cien AJ, Penny PC, Horn BJ, Popovich JM, Taunt CJ. Comparison between liposomal bupivacaine and femoral nerve block in patients undergoing primary total knee arthroplasty. J Surg Orthop Adv, 2015, 24: 225–229.
30. Emerson RH Jr, Barrington JW, Olugbode O, Lovald S, Watson H, Ong K. Femoral nerve block versus long-acting wound infiltration in total knee arthroplasty. Orthopedics, 2016, 39: e449–e455.
31. Horn BJ, Cien A, Reeves NP, Pathak P, Taunt CJ Jr. Femoral nerve block vs periarticular bupivacaine liposome injection after primary total knee arthroplasty: effect on patient outcomes. J Am Osteopath Assoc, 2015, 115: 714–719.
32. Kirkness CS, Asche CV, Ren J, Kim M, Rainville EC. Cost-benefit evaluation of liposomal bupivacaine in the management of patients undergoing total knee arthroplasty. Am J Health Syst Pharm, 2016, 73: e247–e254.
33. Yu S, Szulc A, Walton S, Bosco J, Iorio R. Pain control and functional milestones in total knee arthroplasty: liposomal bupivacaine versus femoral nerve block. Clin Orthop Relat Res, 2017, 475: 110–117.
34. Viscusi ER, Sinatra R, Onel E, Ramamoorthy SL. The safety of liposome bupivacaine, a novel local analgesic formulation. Clin J Pain, 2014, 30: 102–110.
35. Lambrechts M, O’Brien MJ, Savoie FH, You Z. Liposomal extended-release bupivacaine for postsurgical analgesia. Patient Prefer Adherence, 2013, 7: 885–890.
36. Goyal N, McKenzie J, Sharkey PF, Parvizi J, Hozack WJ, Austin MS. The 2012 Chitranjan Ranawat award: intraarticular analgesia after TKA reduces pain: a randomized, double-blinded, placebo-controlled, prospective study. Clin Orthop Relat Res, 2013, 471: 64–75.
37. Tibesku CO, Hofer P, Portegies W, Ruys CJ, Fennema P. Benefits of using customized instrumentation in total knee arthroplasty: results from an activity-based costing model. Arch Orthop Trauma Surg, 2013, 133: 405–411.
38. Gittins M, Doucette D. Total joint arthroplasty: tips for improving efficiency. Am J Orthop (Belle Mead NJ), 2014, 43: S1–S4.
39. Pauwse JJ, Thomasen BJ, Weterings J, van Rossum E, Ausems ME. Femoral nerve block using ropivacaine 0.025%, 0.05% and 0.1%: effects on the rehabilitation programme following total knee arthroplasty: a pilot study. Anaesthesia, 2008, 63: 948–953.
40. Sharma S, Iorio R, Specht LM, Davies-Lepie S, Healy WL. Complications of femoral nerve block for total knee arthroplasty. Clin Orthop Relat Res, 2010, 468: 135–140.